Genel

Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS® (raltegravir) 600 mg in the European Union




Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Committee for Medicinal Products for Human
Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approval of ISENTRESS® (raltegravir) 600
mg film-coated tablets, in combination with other anti-retroviral
medicinal products, for the treatment of HIV-1 infection in adults and
pediatric patients weighing at least 40 kg.

Language:
English

Contact:

Merck
Media:
Pam Eisele, 267-305-3558
or
Carmen de Gourville, 267-305-4195
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK

Exchange:
NYSE

read more

Click to comment

Leave a Reply

E-posta hesabınız yayımlanmayacak. Gerekli alanlar * ile işaretlenmişlerdir

To Top